# Antibiotic intermediates (6-APA, 7-ACA): Regulation

Why penicillin plants must stand apart from other drugs

Source page: https://www.materialinsights.org/chemicals/antibiotic_intermediates/regulation/

What this tab covers How it is regulated and what could disrupt supply: hazard classification, rules in the EU, US and India, anti-dumping duties and other trade measures, and supply-risk notes.

#### Hazards

| Classification | UN number | Key risks |
|---|---|---|
| respiratory sensitisation cat 1, skin sensitisation cat 1 (penicillins) | not regulated | Penicillin allergy means beta-lactams must be made in segregated facilities. |

#### Main rules

| Where | Rule | Effect |
|---|---|---|
| **US** | 21 CFR 211.42(d) and FDA guidance require separate facilities for penicillin and cephalosporin products | dedicated plants raise capital cost |
| **Global** | AMR Industry Alliance antibiotic manufacturing standard (discharge limits) | pressure on effluent from fermentation and API sites |

#### India

| Rule | Effect |
|---|---|
| **PLI fermentation category: incentive of 20% of sales in early years** | made Lyfius viable |
| **MIP via DGFT (Jan 2026)** | floor price on imports for one year |
| **CPCB effluent standards; draft antibiotic residue limits** | tighter effluent rules (indicative) |

#### Trade measures

- MIP on penicillin G, 6-APA, amoxicillin (2026)
- DGTR anti-dumping: penicillin G (China), 6-APA (China, EU), amoxicillin trihydrate (China), Sept 2026

#### Supply risk

One of the most concentrated pharma chains: China supplies most world penicillin G, 6-APA and 7-ACA. Several governments list beta-lactam intermediates as strategic.

## Other sections

- [Summary](https://www.materialinsights.org/chemicals/antibiotic_intermediates/index.md)
- [Overview](https://www.materialinsights.org/chemicals/antibiotic_intermediates/overview/index.md)
- [Correlation](https://www.materialinsights.org/chemicals/antibiotic_intermediates/correlation/index.md)
- [Production route](https://www.materialinsights.org/chemicals/antibiotic_intermediates/routes/index.md)
- [Production](https://www.materialinsights.org/chemicals/antibiotic_intermediates/production/index.md)
- [Feedstocks](https://www.materialinsights.org/chemicals/antibiotic_intermediates/feedstocks/index.md)
- [Cycles](https://www.materialinsights.org/chemicals/antibiotic_intermediates/cycles/index.md)
- [Trading](https://www.materialinsights.org/chemicals/antibiotic_intermediates/trading/index.md)
- [Movement](https://www.materialinsights.org/chemicals/antibiotic_intermediates/movement/index.md)
- [Characteristics](https://www.materialinsights.org/chemicals/antibiotic_intermediates/characteristics/index.md)
- [Emissions](https://www.materialinsights.org/chemicals/antibiotic_intermediates/emissions/index.md)
- [Relationships](https://www.materialinsights.org/chemicals/antibiotic_intermediates/links/index.md)